Phase III, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of Seqirus¿ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and a US-licensed QIV in Healthy Subjects aged 6 Months through 47 Months

Project Details

Funding

  • Syneos Health: $35,148.50

Keywords

  • Biotechnology & Drug Development, Immunology